These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

175 related items for PubMed ID: 31669704

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Small-cell Carcinomas of the Urinary Bladder and Prostate: TERT Promoter Mutation Status Differentiates Sites of Malignancy and Provides Evidence of Common Clonality Between Small-cell Carcinoma of the Urinary Bladder and Urothelial Carcinoma.
    Priemer DS, Wang M, Zhang S, Lopez-Beltran A, Kouba E, Montironi R, Davidson DD, MacLennan GT, Wang L, Osunkoya AO, Deng Y, Emerson RE, Cheng L.
    Eur Urol Focus; 2018 Dec; 4(6):880-888. PubMed ID: 28753872
    [Abstract] [Full Text] [Related]

  • 3. Telomerase reverse transcriptase promoter mutations in glandular lesions of the urinary bladder.
    Vail E, Zheng X, Zhou M, Yang X, Fallon JT, Epstein JI, Zhong M.
    Ann Diagn Pathol; 2015 Oct; 19(5):301-5. PubMed ID: 26239299
    [Abstract] [Full Text] [Related]

  • 4. Telomerase reverse transcriptase promoter mutations in bladder cancer: high frequency across stages, detection in urine, and lack of association with outcome.
    Allory Y, Beukers W, Sagrera A, Flández M, Marqués M, Márquez M, van der Keur KA, Dyrskjot L, Lurkin I, Vermeij M, Carrato A, Lloreta J, Lorente JA, Carrillo-de Santa Pau E, Masius RG, Kogevinas M, Steyerberg EW, van Tilborg AA, Abas C, Orntoft TF, Zuiverloon TC, Malats N, Zwarthoff EC, Real FX.
    Eur Urol; 2014 Feb; 65(2):360-6. PubMed ID: 24018021
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. TERT Promoter Mutation Analysis of Whole-Organ Mapping Bladder Cancers.
    Weyerer V, Eckstein M, Strissel PL, Wullweber A, Lange F, Tögel L, Geppert CI, Sikic D, Taubert H, Wach S, Wullich B, Hartmann A, Stoehr R, Giedl J.
    Genes (Basel); 2021 Feb 05; 12(2):. PubMed ID: 33562516
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. TERT promoter mutations identify a high-risk group in metastasis-free advanced thyroid carcinoma.
    Bournaud C, Descotes F, Decaussin-Petrucci M, Berthiller J, de la Fouchardière C, Giraudet AL, Bertholon-Gregoire M, Robinson P, Lifante JC, Lopez J, Borson-Chazot F.
    Eur J Cancer; 2019 Feb 05; 108():41-49. PubMed ID: 30648628
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. TERT mRNA Expression as a Novel Prognostic Marker in Papillary Thyroid Carcinomas.
    Tanaka A, Matsuse M, Saenko V, Nakao T, Yamanouchi K, Sakimura C, Yano H, Nishihara E, Hirokawa M, Suzuki K, Miyauchi A, Eguchi S, Yoshiura KI, Yamashita S, Nagayasu T, Mitsutake N.
    Thyroid; 2019 Aug 05; 29(8):1105-1114. PubMed ID: 31286848
    [Abstract] [Full Text] [Related]

  • 20. Implications of TERT promoter mutations and telomerase activity in urothelial carcinogenesis.
    Günes C, Wezel F, Southgate J, Bolenz C.
    Nat Rev Urol; 2018 Jun 05; 15(6):386-393. PubMed ID: 29599449
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.